United States Allergy Treatment Market Report by Type, Treatment, Dosage Form, Distribution Channel, States and Company Analysis, 2026-2034

United States Allergy Treatment Market Size & Forecast 2026-2034

United States allergy treatment market is expected to see steady growth from US$ 6.33 billion in 2025 to US$ 10.61 billion by 2034, at a compound annual growth rate of 5.91% from 2026 to 2034. Increasing pervasiveness of allergy, enhanced awareness regarding advanced therapies, increasing adoption of immunotherapy, and continued new innovations in biologics and antihistamine treatments in the overall US healthcare will drive market growth.

United States Allergy Treatment Market Outlook

Allergy treatment describes a group of medical measures taken for the purposes of prevention, management, and alleviation of the symptoms resulting from an allergic response to materials such as pollen, dust mites, foodstuffs, insect venom, and a few medications. Other classes of treatment options are antihistamines, decongestants, corticosteroids, leukotriene modifiers, and advanced biologic therapies that target specific immune pathways. Immunotherapy, both given through allergy shots or sublingual tablets, is also widely used as long-term relief by gradually desensitizing the immune system to allergens.

Allergy treatment is very popular in the United States, given that allergic rhinitis, asthma, food allergies, and eczema are fairly common conditions. Environmental factors, urbanization, changes in lifestyle, and increased exposure to allergens are strengthening the diagnosis rate. The US healthcare system promotes excellent access to allergy specialists, state-of-the-art diagnostics, and newer therapies-including biologics. Increasing awareness among patients, direct-to-consumer advertising, and a focus on quality of life have accelerated the uptake of allergy treatments throughout the country.

Growth Driver in the United States Allergy Treatment Market

Increasing Prevalence of Allergic Conditions

The rising prevalence of allergic diseases is a key growth driver in the United States allergy treatment market. Allergic rhinitis, asthma, food allergies, eye allergies, and atopic dermatitis are some allergic conditions that affect millions of people in the United States irrespective of age. Higher diagnosis rates in the country are supported by increasing environmental pollution, climate change, urban lifestyles, and longer exposure to allergens. Increased rates of more people suffering from chronic or recurrent symptoms boost demand for effective long-term treatment options. Early diagnosis and disease management have been increasingly encouraged as a result to decrease hospital admissions and improve quality of life. A growing patient pool thus keeps demanding prescription therapies, over-the-counter medications, and immunotherapy solutions consistently, thereby underpinning strong, continued market growth. In 2021, almost 1 in 3 adults and more than 1 in 4 children in the United States reported having a seasonal allergy, eczema, or food allergy. According to statistics from CDC's National Center for Health Statistics, 27.2% of children have allergy symptoms, and 31.8% of adults, which counts over 100 million people.

Innovation in Advanced and Biologic Therapies

Technological and pharmaceutical innovation has significantly accelerated growth in the allergy treatment market of the U.S. The introduction of biologic therapies targeting certain immune pathways has revolutionized treatment options for patients suffering from severe or treatment-resistant allergic diseases. New biologics exhibit better efficacy with few side effects compared to conventional drugs. Moreover, the advancement of immunotherapy has witnessed an increase in treatment options that were mostly dominated by traditional injections, including sublingual and oral formulations. Heavy investments by pharmaceutical companies in research and development have introduced new formulations and delivery methods into the market. This innovation-intensive environment supports premium pricing, higher adoption rates, and long-term patient adherence, which is strengthening the overall growth. Feb 2024 - The U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure to one or more foods. Patients who take Xolair must continue to avoid foods they are allergic to. Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

Increase awareness and concentrate on preventive health care

Growing awareness about allergic conditions and their long-term impact has driven patients to seek early and consistent treatment. Public education campaigns, better access to allergists, and widespread use of diagnostic testing have increased allergy identification rates. Employers and insurers are also promoting preventive healthcare in order to minimize long-term costs associated with unmanaged allergies. Preventive approaches, including regular medication use and immunotherapy, are gaining acceptance among patients. This shift from symptom-only management to long-term control has lengthened treatment duration and frequency, boosting recurring revenue across drug therapies, immunotherapy, and supportive care products throughout the U.S. market. September 2025—FARE (Food Allergy Research & Education) announced the release of a new public service announcement, RISE. Using dance as a metaphor, the PSA encourages the 33 million people in the U.S. living with food allergy to rise above the fear by learning their options, being connected to the community, and taking action. The PSA is sponsored by Genentech, a member of the Roche Group, and Novartis Pharmaceutical Corporation.

Challenge in the United States Allergy Treatment Market

High Value of Advanced Therapies

One of the key challenges in the US allergy treatment market is the very high cost associated with advanced therapies, namely biologics and long-term immunotherapy. Most of these therapies, by their very nature, are ongoing and require specialty care that creates a high financial burden for patients. Insurance coverage is highly variable, and out-of-pocket costs are one of the major barriers to access for many. Cost concerns might lead to delaying treatment initiation or discontinuing therapy, which will impact overall effectiveness. Balancing innovation with affordability continues to be a challenge for healthcare providers and manufacturers alike and can contribute to slowing down market penetration for high-value therapies.

Treatment Adherence and Lengthy Therapy Duration

Particularly, treatments against allergies, including immunotherapy, often demand commitment for several years in order to obtain more permanent benefits. Poor patient compliance due to inconvenience, side effects, or slow symptom improvement reduces the success of treatments. Most patients prematurely discontinue therapy and limit clinical outcomes or market growth. Oral and injectable regimens may be perceived as burdensome, especially for pediatric or elderly patients. Of importance, improving adherence through better patient education, simplified dosing, and convenient delivery methods continues to be an important strategy for maximizing the effectiveness and commercial potential of allergy treatments.

United States Eye Allergy Treatment Market

Driven by the high incidence of seasonal and perennial allergic conjunctivitis, the US market for eye allergy treatments is highly proliferating. Factors such as pollen, dust, pet dander, and environmental pollution are some of the common allergens. Some of the key categories of eye allergy treatments include antihistamine eye drops, mast cell stabilizers, corticosteroids, and combinations. Rising screen time, paired with increased levels of environmental pollution, has made the situation worse, thereby fueling the market for eye allergy treatments. Prescription, as well as over-the-counter medicines, are largely used due to the strong pharmacy channel distribution in the US.

United States - Food Allergy Treatment Market

The food allergy treatment market is changing in the United States beyond the usual methods that people follow to avoid allergens. The awareness about the severity of food allergies, particularly among children, has boosted the requirement for effective treatments. Emergency and supportive treatments for food allergies have also been increasingly accepted among healthcare providers. Parents and caregivers of children with food allergies have been becoming more proactive in looking for treatments that would minimize the seriousness and risks posed by food allergies. The market is also supplemented by awareness about school and emergency preparedness.

United States Anti-Allergy Drugs Market

Anti-allergy medications are a mature but growing market in the U.S. allergy treatment market. Antihistamines, glucocorticoids, and leukotriene inhibitors are the largely prescribed medications for the treatment of both short-term and long-term allergies. Over-the-counter medications have increased accessibility, thereby encouraging large volumes of sales. Prescription medications are necessary in the case of moderate or severe allergy, when stronger medications are needed to control the symptoms. Combination medications and extended-release medications are increasingly becoming common due to their ease and efficacy. The market has strong brand recognition, a process of reformulation, and large retailers.

United States Oral Allergy Treatment Market

The demand for oral allergy medications, including tablets, oral syrups, and oral immunotherapy medications, is on the rise, and this is attributed to their convenience in terms of administration. These medications are most sought after by children and patients looking for alternates to injections. The oral form of medications helps with compliance, as these medications can be easily incorporated into one’s lifestyle. In addition, improvements in formulation technologies have improved stability, and oral medications continue to expand into various disease indications. The rising acceptance of oral immunotherapy by professionals is expected to increase its significance in allergy management in the U.S. market.

United States Allergy Treatment Retail Pharmacies Industry

Retail pharmacies are one of the most prominent distribution channels for allergy medications sold in the United States. Their widespread locations, extended operating hours, and convenience of providing both prescription and over-the-counter medications to their patients and clients make them the first sources of treatment for many. Pharmacists are also recognized as influential players in patient education and decision-making regarding medications. This trend favoring chain pharmacies and online prescription services has added to the strength of the distribution channel. The seasonality and repetitive purchases add to their importance as key revenue contributors to the overall market.

California Allergy Treatment Market

The California region caters to some of the largest markets for allergical treatments in the US, owing to regional population density, diverse climatic zones, and higher exposure to allergens. Wildfires, pollution, and pollen levels are some reasons why higher cases of allergies are found in this region. The region boasts an advanced healthcare system that allows prompt diagnoses followed by advanced treatments for such allergies. The region also stands home to pharmaceutical innovation developments that facilitate smooth adaptation to newer treatments.

New York Allergy Treatment Market

The market for allergy treatments in the New York area has factors such as metropolitan lifestyle, pollution, and seasonal allergens contributing to this market. Also, the well-structured healthcare system in the state enables effective treatment of allergies. High awareness among patients coupled with accessibility to specialists leads to the demand for both medication and immunotherapy. Both retail pharmacies and hospitals form a significant component of the distribution chain.

Washington Allergy Treatment Market

The allergy treatment market in Washington is affected by various environmental allergens, including pollen, molds, and moisture. The seasonal fluctuations ensure that there is a steady demand for allergy medications. The focus of Washington on preventive healthcare is a factor that promotes adoption of treatments. The state has modern healthcare infrastructure, and there is awareness about allergy treatments, which creates a strong base for growth.

New Jersey Allergy Treatment Market

Being a densely populated state near major cities contributes to a high prevalence of allergies in New Jersey. It is an advantage to the market because allergy treatment is in high demand. Additionally, the presence of top healthcare institutions and pharmaceutical firms in New Jersey is a plus to the allergy treatment market. This is because high insurance coverage of allergy treatment enables the population to conveniently acquire treatment.

Market Segmentations

Type

• Eye Allergy
• Skin Allergy
• Food Allergy
• Asthma
• Rhinitis
• Others

Treatment

• Anti-Allergy Drugs
• Immunotherapy

Dosage Form

• Oral
• Inhalers
• Intranasal
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Retailers
• Others

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis

• AbbVie Inc.
• ALK-Abelló A/S
• ALLERGOPHARMA GmbH & Co. KG
• Almirall, S.A
• DBV Technologies
• GSK plc.
• HAL Allergy B.V.
• Novartis Pharmaceuticals Corporation
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Report Details: